

Heidelberg Pharma AG (HPHA) - Financial and Strategic SWOT Analysis Review

<https://marketpublishers.com/r/H34C484463EEN.html>

Date: November 2021

Pages: 56

Price: US\$ 125.00 (Single User License)

ID: H34C484463EEN

Abstracts

Heidelberg Pharma AG (HPHA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description – A detailed description of the company's operations and business divisions.

Corporate strategy – Analyst's summarization of the company's business strategy.

SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history – Progression of key events associated with the company.

Major products and services – A list of major products, services and brands of the company.

Key competitors – A list of key competitors to the company.

Key employees – A list of the key executives of the company.

Executive biographies – A brief summary of the executives' employment history.

Key operational heads – A list of personnel heading key departments/functions.

Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.

Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Heidelberg Pharma AG (Heidelberg Pharma) is a biopharmaceutical company that develops novel therapeutics for the treatment and specific detection of various cancers. Heidelberg Pharma's pipeline products are focused on treating multiple myeloma, prostate cancer, hematological cancers, non-hodgkin lymphoma, blood cancers, generic diseases and solid tumors. Through its subsidiary Heidelberg Pharma Research GmbH provides preclinical contract research services and is the first company to develop the toxin Amanitin into oncology therapies using its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology platform. Heidelberg Pharma is headquartered in Ladenburg, Germany.

Heidelberg Pharma AG Key Recent Developments

Jul 08,2021: Heidelberg Pharma reports on first half-year 2021

Jan 03,2021: Heidelberg Pharma Expands Management Team

Oct 22,2020: Heidelberg Pharma contracts ProBioGen for cell line development and manufacturing services

Oct 08,2020: Heidelberg Pharma : Interim Management Statement on the First Nine Months of 2020

Sep 14,2020: Heidelberg Pharma receives milestone payment from Partner Magenta

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

Heidelberg Pharma AG - Key Facts
Heidelberg Pharma AG - Key Employees
Heidelberg Pharma AG - Key Employee Biographies
Heidelberg Pharma AG - Major Products and Services
Heidelberg Pharma AG - History
Heidelberg Pharma AG - Company Statement
Heidelberg Pharma AG - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
Heidelberg Pharma AG - Business Description
Business Segment: ADC Technology Sales Revenue
Performance
Business Segment: Out-licensing Sales Revenue
Performance
Business Segment: Service Business Sales Revenue
Performance
Geographical Segment: Europe
Performance
Geographical Segment: Germany
Performance
Geographical Segment: Rest of the World
Performance
Geographical Segment: The US
Performance
Heidelberg Pharma AG - Corporate Strategy
Heidelberg Pharma AG - SWOT Analysis
SWOT Analysis - Overview
Heidelberg Pharma AG - Strengths
Heidelberg Pharma AG - Weaknesses
Heidelberg Pharma AG - Opportunities
Heidelberg Pharma AG - Threats

Heidelberg Pharma AG - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios

Financial Ratios - Annual Ratios

Performance Chart

Financial Performance

Financial Ratios - Interim Ratios

Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021

Heidelberg Pharma AG, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Jul 08, 2021: Heidelberg Pharma reports on first half-year 2021

Jan 03, 2021: Heidelberg Pharma Expands Management Team

Oct 22, 2020: Heidelberg Pharma contracts ProBioGen for cell line development and manufacturing services

Oct 08, 2020: Heidelberg Pharma : Interim Management Statement on the First Nine Months of 2020

Sep 14, 2020: Heidelberg Pharma receives milestone payment from Partner Magenta

Jul 09, 2020: Heidelberg Pharma reports on first half-year 2020

Apr 23, 2020: Heidelberg Pharma: Interim management statement on the first three months of 2020

Mar 19, 2020: Heidelberg Pharma announces financial figures for fiscal year 2019 and provides business update

Mar 04, 2020: Heidelberg Pharma: US patent rights granted for diagnosis and treatment of patients with TP53/RNA polymerase II deletion

Jan 22, 2020: Heidelberg Pharma secures financing commitment from its main shareholder dievini

SECTION 6 – APPENDIX

[Methodology](#)
[Ratio Definitions](#)
[About GlobalData](#)
[Contact Us](#)
[Disclaimer](#)

List Of Tables

LIST OF TABLES

Heidelberg Pharma AG, Key Facts
Heidelberg Pharma AG, Key Employees
Heidelberg Pharma AG, Key Employee Biographies
Heidelberg Pharma AG, Major Products and Services
Heidelberg Pharma AG, History
Heidelberg Pharma AG, Subsidiaries
Heidelberg Pharma AG, Key Competitors
Heidelberg Pharma AG, Ratios based on current share price
Heidelberg Pharma AG, Annual Ratios
Heidelberg Pharma AG, Annual Ratios (Cont...1)
Heidelberg Pharma AG, Annual Ratios (Cont...2)
Heidelberg Pharma AG, Interim Ratios
Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Heidelberg Pharma AG, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Heidelberg Pharma AG, Performance Chart (2016 - 2020)

Heidelberg Pharma AG, Ratio Charts

Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021

I would like to order

Product name: Heidelberg Pharma AG (HPHA) - Financial and Strategic SWOT Analysis Review

Product link: <https://marketpublishers.com/r/H34C484463EEN.html>

Price: US\$ 125.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/H34C484463EEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970